Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:ALVRNASDAQ:CCCCNASDAQ:REPLNASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.48-1.7%$1.35$0.87▼$6.78$150.99M0.74836,600 shs233,289 shsALVRAlloVir$2.50-2.3%$3.45$7.96▼$24.15$12.61M0.6315,312 shs35,701 shsCCCCC4 Therapeutics$1.49-2.0%$1.49$1.09▼$7.66$105.09M2.941.31 million shs728,171 shsREPLReplimune Group$9.45-1.0%$9.05$6.44▼$17.00$724.61M0.61865,323 shs581,094 shsRGNXREGENXBIO$8.73+1.3%$8.99$5.04▼$15.36$438.40M1.06928,192 shs423,944 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-1.67%-1.67%-0.34%+44.61%-66.55%ALVRAlloVir-0.78%-1.54%-14.67%-65.41%-84.86%CCCCC4 Therapeutics-1.97%-1.97%+0.68%+13.74%-67.25%REPLReplimune Group-1.05%-0.11%-1.87%+26.68%+16.81%RGNXREGENXBIO+1.28%-0.23%-13.82%+38.79%-19.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.6498 of 5 stars3.13.00.04.50.02.50.0ALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/ACCCCC4 Therapeutics1.7541 of 5 stars3.31.00.00.00.01.70.6REPLReplimune Group4.1047 of 5 stars3.61.00.04.51.82.50.6RGNXREGENXBIO4.5266 of 5 stars3.43.00.04.62.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00171.19% UpsideALVRAlloVir 0.00N/AN/AN/ACCCCC4 Therapeutics 2.50Moderate Buy$12.00705.37% UpsideREPLReplimune Group 3.13Buy$20.83120.46% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63262.26% UpsideCurrent Analyst Ratings BreakdownLatest REPL, ALVR, RGNX, ALEC, and CCCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/20/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight6/9/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.006/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.47N/AN/A$1.29 per share1.14ALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ACCCCC4 Therapeutics$35.58M2.97N/AN/A$3.06 per share0.49REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ARGNXREGENXBIO$83.33M5.25N/AN/A$5.24 per share1.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)ALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)CCCCC4 Therapeutics-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)REPLReplimune Group-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/6/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)Latest REPL, ALVR, RGNX, ALEC, and CCCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.103.343.34ALVRAlloVirN/A86.7886.78CCCCC4 TherapeuticsN/A5.705.70REPLReplimune Group0.177.957.95RGNXREGENXBION/A2.932.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ALVRAlloVir66.05%CCCCC4 Therapeutics78.81%REPLReplimune Group92.53%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%ALVRAlloVir32.07%CCCCC4 Therapeutics8.73%REPLReplimune Group8.80%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million90.89 millionOptionableALVRAlloVir1105.04 million3.43 millionOptionableCCCCC4 Therapeutics15071.01 million64.81 millionOptionableREPLReplimune Group21077.09 million70.30 millionOptionableRGNXREGENXBIO37050.16 million43.75 millionOptionableREPL, ALVR, RGNX, ALEC, and CCCC HeadlinesRecent News About These CompaniesJanney Montgomery Scott LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)July 4 at 3:11 AM | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 30, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 16, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?June 11, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Regenxbio Through 8 AnalystsJune 9, 2025 | benzinga.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan CapitalJune 9, 2025 | marketbeat.comRegenxbio's RGX-121 Could Become The New Standard Of Care In Hunter SyndromeJune 6, 2025 | seekingalpha.comOtsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne updateJune 6, 2025 | biopharmadive.comBRegeNXBio shares fall, despite positive new data on RGX-202June 6, 2025 | thepharmaletter.comTRegenxbio’s Duchenne gene therapy data positive as shares falterJune 5, 2025 | bioworld.comBRegenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene TherapyJune 5, 2025 | biospace.comBREGENXBIO updates Phase 1/2 data for Duchenne candidateJune 5, 2025 | msn.comEarly Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, LongerJune 5, 2025 | benzinga.comREGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202June 5, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 5, 2025 | marketbeat.comREGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202June 2, 2025 | prnewswire.comRegenxbio at RBC Conference: Strategic Moves and Clinical ProgressMay 22, 2025 | investing.comREGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 20, 2025 | finanznachrichten.deREGENXBIO announces royalty monetization agreement for up to $250MMay 20, 2025 | msn.comREGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 19, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in StockMay 15, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModePayment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?By Gabriel Osorio-Mazilli | June 23, 2025View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?REPL, ALVR, RGNX, ALEC, and CCCC Company DescriptionsAlector NASDAQ:ALEC$1.48 -0.03 (-1.67%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$1.48 0.00 (0.00%) As of 07/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.AlloVir NASDAQ:ALVR$2.50 -0.06 (-2.34%) As of 07/3/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.C4 Therapeutics NASDAQ:CCCC$1.49 -0.03 (-1.97%) Closing price 07/3/2025 03:37 PM EasternExtended Trading$1.48 -0.01 (-1.01%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Replimune Group NASDAQ:REPL$9.45 -0.10 (-1.05%) Closing price 07/3/2025 03:03 PM EasternExtended Trading$9.48 +0.03 (+0.26%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.REGENXBIO NASDAQ:RGNX$8.73 +0.11 (+1.28%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$8.74 +0.00 (+0.06%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
